Stockscreener 앱 받기
1.91
8.52%
0.15
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics Inc. stock trend forecastSwing Trade & High Conviction Investment Ideas - Newser
Is this a good reentry point in CytomX Therapeutics Inc.Portfolio Performance Summary & Weekly Watchlist of Top Performers - Newser
News impact scoring models applied to CytomX Therapeutics Inc.2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
What institutional flow reveals about CytomX Therapeutics Inc.July 2025 Drop Watch & Daily Market Momentum Tracking - Newser
Analyzing CytomX Therapeutics Inc. with multi timeframe chartsPortfolio Risk Report & Safe Swing Trade Setup Alerts - Newser
Identifying reversal signals in CytomX Therapeutics Inc.Weekly Profit Analysis & Weekly Market Pulse Alerts - Newser
Technical analysis overview for CytomX Therapeutics Inc. stockJuly 2025 Pullbacks & Long-Term Growth Plans - Newser
What makes CytomX Therapeutics Inc. stock price move sharplyShare Buyback & High Return Trade Guides - sundaytimes.kr
CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest
Published on: 2025-08-15 21:04:24 - sundaytimes.kr
CytomX to continue Phase I ADC trial despite patient death - Yahoo Finance
CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest
Is CytomX Therapeutics Inc. stock poised for growth2025 Technical Overview & Community Consensus Picks - Newser
RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN
Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛
Is CytomX Therapeutics Inc. reversing from oversold territory2025 Key Highlights & Community Verified Swing Trade Signals - Newser
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
HC Wainwright Issues Pessimistic Outlook for CTMX Earnings - Defense World
Published on: 2025-08-13 07:49:54 - sundaytimes.kr
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - NewsBreak: Local News & Alerts
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks
CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
CytomX Therapeutics Announces Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus
CytomX Therapeutics files $250M mixed securities shelf - AInvest
CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest
CytomX Therapeutics beats Q2 revenue estimates - MarketScreener
0.41%
0.88%
자본화:
|
볼륨(24시간):